Solesence, INC. 8-K Filing
Ticker: SLSN · Form: 8-K · Filed: Dec 3, 2025 · CIK: 883107
Sentiment: neutral
Filing Stats: 603 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-12-02 19:11:43
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share SLSN The NASDAQ S
- $366,912 — ce pay in the aggregate gross amount of $366,912. Mr. Jankowski will also receive accele
Filing Documents
- f8k_120225.htm (8-K) — 23KB
- exh_101.htm (EX-10.1) — 49KB
- 0001171843-25-007730.txt ( ) — 244KB
- slsn-20251124_lab.xml (EX-101.LAB) — 33KB
- slsn-20251124_pre.xml (EX-101.PRE) — 22KB
- slsn-20251124.xsd (EX-101.SCH) — 3KB
- f8k_120225_htm.xml (XML) — 3KB
02. Departure
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. The Company previously reported on a Current Report on Form 8-K dated December 1, 2025 that former CEO, Jess Jankowski had resigned as an officer of the Company. Subsequently, the Company entered into a Separation Agreement and General Release of All Claims, effective as of December 2, 2025, with Mr. Jankowski (the "Separation Agreement"). Pursuant to the Separation Agreement, Mr. Jankowski will receive severance pay in the aggregate gross amount of $366,912. Mr. Jankowski will also receive accelerated vesting of all outstanding options previously granted to Mr. Jankowski. Furthermore, during the period severance will be paid, the Company will pay the monthly insurance premiums for Mr. Jankowski's participation in the Company's group health insurance plan through COBRA. In consideration of these and other benefits provided under the Separation Agreement, Mr. Jankowski agreed to release any and all claims against the Company and its representatives and confirmed his continuing obligations to the Company including compliance with certain restrictive covenants and assisting the Company, at its request, in certain potential disputes. The Separation Agreement is filed hereto as Exhibit 10.1 and is incorporated herein by reference. The descriptions thereof contained in this Form 8-K are qualified in all respects by the terms and provisions of the Separation Agreement.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 10.1 Confidential Separation Agreement and Release, dated November 24, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Confidential portions of this exhibit have been redacted.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 2, 2025 SOLSENCE, INC. By: /s/ Laura Riffner Name: Laura Riffner Title: CFO